Pain Relieving Drugs Market Forecast 2014-2024

LONDON, September 22, 2014 /PRNewswire/ --

Future Prospects for Leading Companies 

Report Details  

Pain relieving drugs - new study showing you trends, R&D progress, and predicted revenues
Where is the pain relieving drugs market heading? What are the commercial prospects for this market and related technologies? See what the future holds for painkillers. Visiongain's new report shows you potential revenues and other trends to 2024, discussing data, opportunities and prospects.

Our 323 page report provides 265 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at world market, submarket and national level. You will see financial results, interviews, trends, opportunities and revenue predictions. Much opportunity remains in this growing pharma market.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

Forecasts from 2014-2024 and other analyses show you commercial prospects
Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and STEP), company profiles and commercial developments. Read the full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
•  Dr Stephen K Doberstein, Senior Vice President and Chief Scientific Officer, Nektar Therapeutics
•  Dr Tom McCarthy, Chief Executive Officer, Spinifex Pharmaceuticals

You find prospects for key submarkets
In addition to analyses of the overall world market, you see revenue forecasts for these six submarkets to 2024:
•  Narcotic pain relieving drugs
•  Neuropathic pain relieving drugs
•  Treatments for arthritis
•  Non-Narcotic pain relieving drugs
•  Treatments for migraines
•  Other pain relieving drugs

Technologies that improve on the tolerance and dependence issues associated with pain relieving drugs will achieve success. The increasing use of abuse-resistant delivery systems in particular will be a major benefiting factor for pain relieving drugs as a whole.

Our investigation shows business research and analyses with individual revenue forecasts and discussions. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

See revenue forecasts for products
How will leading drugs perform to 2024 at the world level? Our study forecasts sales of 28 products including these brands:
•  Celebrex
•  Voltaren
•  Relpax
•  Lyrica
•  Cymbalta
•  Aspirin
•  Zomig
•  Duragesic
•  Oxycontin ER
•  Panadol
•  Lidoderm

Our study includes OTC (over-the-counter) and Rx (prescription) pain relieving medicines.

Discover how high revenues can go. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

Our analysis also breaks the main world forecast into geographical markets.

What are the prospects for the leading regions and countries?
Developments worldwide will influence the market, especially fast-rising demand in emerging countries. There will be many opportunities for pain-treating products.

In addition to analyses of the overall world market, you discover individual revenue forecasts for 13 national markets to 2024:
•  US
•  Japan
•  Germany
•  France
•  UK
•  Italy
•  Spain
•  Brazil
•  Russia
•  India
•  China
•  Turkey
•  South Korea
•  Rest of the World

Our analyses show sustained growth, particularly for the BRIC nations of Brazil, Russia, India, and China. New product approvals and the development of abuse-resistant drugs will influence market growth.

Regulatory, demographic, and commercial developments worldwide will influence the markets both in the established North American and Western European economies, and the fast-rising emerging markets.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

Research and development activities
What is happening in the R&D pipeline for pain relieving drugs? You see developmental trends, gaining insight into the R&D pipeline for:
•  Narcotic pain relieving drugs
•  Neuropathic pain relieving drugs
•  Anti-Arthritis pain relieving drugs
•  Non-Narcotic pain relieving drugs
•  Anti-Migraine pain relieving drugs

What issues will affect the pain relieving drugs market?
Our new report discusses issues and events affecting the pain relieving drugs market. You will find discussions of many issues and developments, including:
•  Reimbursement, regulations, patent expiries, generic competition and OTC switching
•  Cost savings and efficiencies
•  Anti-convulsants, analgesics, COX-2 inhibitors, novel opioids, cannabinoids and local anaesthetics
•  Overcoming drug tolerance and dependence
•  The use of biologics (e.g. monoclonal antibodies, MAbs,) for rheumatoid arthritis (RA)
•  Disease modifying anti-rheumatic drugs (DMARDs)
•  Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and aldose reductase inhibitors
•  Understanding pain pathways and mechanisms of action
•  Safety and patient compliance
•  Clinical evidence supporting product efficacy

Our investigation gives you multi-level business research and analyses with sales forecasts. You see how that industry and market can perform from 2014 to 2024.

Discussions of leading companies and prospects for market growth

What will happen next? The pharmaceutical industry will improve treatments for pain relief and increase revenues from 2014 to 2024. The R&D pipeline is strong.
Overall world revenue for that market area will reach $68.2bn in 2014, our report forecasts. Aging populations and diseases such as cancer, arthritis and diabetes will increase sales of painkillers. Also, improved drug delivery and new formulations will be important.

You find discussions of Pfizer, GSK, Johnson & Johnson, Bristol-Myers Squibb and other developers and manufacturers. This decade, many opportunities will arise.  

How the Pain Relieving Drugs Market Forecast 2014-2024: Future Prospects for Leading Companies report helps you
In summary our 323 page report gives you the following knowledge:
•  Revenues forecast to 2024 for the overall pain relieving drugs market and 6 submarkets - discover the industry's prospects, finding promising technology areas for investments and revenues
•  Predicted revenues of 28 leading drugs to 2024 - discover prospects for the leading pain relieving drugs with forecasted revenues provided to 2024
•  Revenue forecasts to 2024 for 13 leading national markets - US, Japan, Germany, France, the UK, Italy, Spain, Brazil, Russia, India, China, Turkey, South Korea and Rest of the World
•  Assess leading companies - hear about products, results and strategies including recent activities and outlook for companies such as GSK, Johnson & Johnson, and Pfizer
•  Review of R&D pipelines - investigate developmental trends and progress
•  Discussion of what stimulates and restrains companies and the market
•  Prospects for established firms and those seeking to enter the market
•  View opinions from our survey, seeing interviews with industry authorities

You will find quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the treatment of pain. You will find data, trends and predictions. Please order our report now.

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel : +44 (0) 20 7336 6100

Or click on https://www.visiongain.com/Report/1319/Pain-Relieving-Drugs-Market-Forecast-2014-2024

Companies Listed  

AB Science
Abbott Laboratories
AcelRx Pharmaceuticals
Actavis (Watson)
Acura
Afferent Pharmaceuticals
Alkem Laboratories
Allergan
Almirall
AlphaPharm
Alza Corporation
Amgen
Aoxing Pharmaceutical Company Inc  
Apotex Corp
Arcion Therapeutics
Ascend Laboratories
AstraZeneca
Avanir
Bayer
Biodelivery Sciences
Biogen Idec
Boston Millennia Partners
Brigham Young University (BYU)
Bristol-Myers Squibb
Care Capital
Celltrion
CeNeS
Centocor Ortho Biotech (J&J)
Chugai
Cilag GmbH International (J&J)
CK Life Sciences
Collegium
CoLucid Pharmaceuticals
Convergence Pharmaceuticals
Depomed
Domain Associates
Dr Reddy's Laboratories
Durect
Eisai
Eli Lilly
Endo Pharmaceuticals
Eurocept BV
Exemplar Pharma
Forest Laboratories
Frazer Healthcare Ventures
Galen
Genentech (Roche)
Genmab
Gilead Sciences
GlaxoSmithKline
Grunenthal Group
Horizon Pharma
Hospira
Human Genome Sciences
Immune Pharmaceuticals
Impax Laboratories
Insys Therapeutics
IVAX Pharmaceuticals
Janssen Pharmaceuticals
Johnson&Johnson
Kaiser Foundation Health Plan Inc
King Pharmaceuticals (Pfizer)
Kyorin
Longitude Capital
Lundbeck
Lupin Pharmaceuticals
McNeil Consumer Healthcare (J&J)
Merck & Co.
Merck Serono
Mitsubishi Tanabe Pharma
Monsanto
Mylan
Nektar Therapeutics
NeurAxon Inc
NeurogesX
Neurotune
Newron Pharmaceuticals
NicOx
Novartis
NuPathe (Teva)
Nuvo Research
Omeros
Ono Pharmaceuticals
Ortho-McNeil-Janssen Pharmaceuticals
Pacira Pharmaceuticals
Pain Therapeutics
Paion
Pappas Ventures
Par Pharmaceutical
Pearl Street Venture Funds
Penwest Pharmaceuticals
Pernix Therapeutics Holding Inc
Pfizer
Pharmacia
PLx Pharma
Pozen Pharmaceuticals
Proteus SA
Purdue Pharma
QRx Pharma
Ranbaxy
Ratiopharm
Rinat (Pfizer)
Roche
Roxane Laboratories
Sandoz (Novartis)
Sanofi
Schering-Plough (Merck & Co)
Shionogi & Co Ltd
Shire
Skye Pharma
Skyline Ventures
Spinifex Pharmaceuticals
Stada Arzneimittel AG
Syntaxin
Takeda
Teikoku
Teva
Triathlon Medical Ventures
UCB
US WorldMeds
Valeant
Watson Pharmaceuticals
WEX Pharmaceuticals
Zars Pharmaceuticals (Nuvo Research)
Zogenix

Organisations Mentioned In The Report
Boston Children Hospital [US]
Center for Medicare and Medicaid Services
Committee for Medicinal Products for Human Use (CHMP)
European Commission
Federal Drug Control Service [Russia]
International Association for the Study of Pain (IASP)
National Institute for Health and Care Excellence (NICE)
The American Pain Society
The Arthritis Foundation
The International Diabetes Federation
The National Institute for Population and Social Security Research (IPSS) [Japan]
US Census Bureau
US Food and Drug Administration (FDA)
US Justice Department
US Patent and Trademark Office
US Society for Neuroscience
World Health Organisation (WHO)

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com